...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's Lead BET Inhibitor ZEN-3694 is Currently Being Evaluated in a Phase 2 Metastatic Prostate Cancer Clinical Trial; Phase 1b/2 TNBC trial with ZEN-3694 and Pfizer’s PARPi, talazoparib, to start in April 2019.

Free
fast facts
recent updates